Prevention of nitrate tolerance by long-term treatment with statins

Cardiovascular Drugs and Therapy

Volumn 17, Issue 2, 2003, Pages 123-128

  Fontaine, David ^a   Otto, Anne ^a   Fontaine, Jeanine ^a   Berkenboom, Guy ^b  

^a UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^b ERASME HOSPITAL   (Belgium)

Author keywords

Atorvastatin; Endothelium; NAD(P)H oxidases; Nitrates; Pravastatin; Rat

Indexed keywords

ATORVASTATIN; CYCLIC GMP; GLYCERYL TRINITRATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LUCIGENIN; N(G) NITROARGININE METHYL ESTER; PHENYLEPHRINE; PRAVASTATIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CHEMOLUMINESCENCE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; IN VIVO STUDY; LONG TERM CARE; MALE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT; STATISTICAL SIGNIFICANCE; THORACIC AORTA; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ANIMALS; AORTA, THORACIC; CHEMILUMINESCENT MEASUREMENTS; DOWN-REGULATION; DRUG ADMINISTRATION SCHEDULE; DRUG TOLERANCE; GUANYLATE CYCLASE; HEPTANOIC ACIDS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INJECTIONS, SUBCUTANEOUS; MALE; NADH, NADPH OXIDOREDUCTASES; NADPH OXIDASE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE III; NITROGLYCERIN; PRAVASTATIN; PYRROLES; RATS; RATS, WISTAR; SUPEROXIDES; VASODILATOR AGENTS;

EID: 0141651564     PISSN: 09203206     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1025383601304     Document Type: Article

References (20)

1. Clancy RM, Leszczynska-Piziak J, Abramson SB. Nitric oxide, an endothelial cell relaxation factor, inhibits neutrophil superoxide anion production via a direct action on the NADPH oxidase. J Clin Invest 1992;90(3):1116-1121.
2. Kaesemeyer WH, Ogonowski AA, Jin L, Caldwell RB, Caldwell RW. Endothelial nitric oxide synthase is a site of superoxide synthesis in endothelial cells treated with glyceryl trinitrate. Br J Pharmacol 2000;131(5):1019-1023.
3. Laursen JB, Somers M, Kurz S, et al. Endothelial regulation of vasomotion in apoE-deficient mice: Implications for interactions between peroxynitrite and tetrahydrobiopterin. Circulation 2001;103(9):1282-1288.
4. Munzel T, Li H, Mollnau H, et al. Effects of long-term nitroglycerin treatment on endothelial nitric oxide synthase (NOS III) gene expression, NOS III-mediated superoxide production, and vascular NO bioavailability. Circ Res 2000;86(1):E7-E12.
5. Fontaine D, Fontaine J, Dupont I, et al. Chronic hydroxymethylglutaryl coenzyme a reductase inhibition and endothelial function of the normocholesterolemic rat: Comparison with angiotensin-converting enzyme inhibition. J Cardiovasc Pharmacol 2002;40(2):172-180.
6. Berkenboom G, Fontaine D, Unger P, Baldassarre S, Preumont N, Fontaine J. Absence of nitrate tolerance after long-term treatment with ramipril: An endothelium-dependent mechanism. J Cardiovasc Pharmacol 1999;34:547-553.
7. Mital S, Zhang X, Zhao G, et al. Simvastatin upregulares coronary vascular endothelial nitric oxide production in conscious dogs. Am J Physiol Heart Circ Physiol 2000;279(6):H2649-H2657.
8. Dostal LA, Whitfield LR, Anderson JA. Fertility and general reproduction studies in rats with the HMG-CoA reductase inhibitor, atorvastatin. Fundam Appl Toxicol 1996;32(2):285-292.
9. Berkenboom G, Langer I, Carpentier Y, Grosfils K, Fontaine J. Ramipril prevents endothelial dysfunction induced by oxidized low-density lipoproteins: A bradykinin-dependent mechanism. Hypertension 1997;30(3 Pt 1):371-376.
10. Abou-Mohamed G, Kaesemeyer WH, Caldwell RB, Caldwell RW. Role of L-arginine in the vascular actions and development of tolerance to nitroglycerin. Br J Pharmacol 2000;130(2):211-218.
11. Wassmann S, Laufs U, Baumer AT, et al. Inhibition of geranylgeranylation reduces angiotensin II-mediated free radical production in vascular smooth muscle cells: Involvement of angiotensin AT1 receptor expression and Rac1 GTPase. Mol Pharmacol 2001;59(3):646-654.
12. Kureishi Y, Luo Z, Shiojima I, et al. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat Med 2000;6(9):1004-1010.
13. Chen Z, Zhang J, Stamler JS. From the Cover: Identification of the enzymatic mechanism of nitroglycerin bioactivation. Proc Natl Acad Sci USA 2002;99(12):8306-8311.
14. Li JM, Shah AM. Differential NADPH- versus NADH-dependent superoxide production by phagocyte-type endothelial cell NADPH oxidase. Cardiovasc Res 2001;52(3):477-486.
15. Griendling KK, Sorescu D, Ushio-Fukai M. NAD(P)H oxidase: Role in cardiovascular biology and disease. Circ Res 2000;86(5):494-501.
16. Mulsch A, Oelze M, Kloss S, et al. Effects of in vivo nitroglycerin treatment on activity and expression of the guanylyl cyclase and cGMP-dependent protein kinase and their downstream target vasodilator-stimulated phosphoprotein in aorta. Circulation 2001;103(17):2188-2194.
17. Schulz E, Tsilimingas N, Rinze R, et al. Functional and biochemical analysis of endothelial (dys)function and NO/cGMP signaling in human blood vessels with and without nitroglycerin pretreatment. Circulation 2002;105(10):1170-1175.
18. Kaesemeyer WH, Caldwell RB, Huang J, Caldwell RW. Pravastatin sodium activates endothelial nitric oxide synthase independent of its cholesterol-lowering actions. J Am Coll Cardiol 1999;33(1):234-241.
19. Nazzaro P, Manzari M, Merlo M, et al. Distinct and combined vascular effects of ACE blockade and HMG-CoA reductase inhibition in hypertensive subjects. Hypertension 1999;33(2):719-725.
20. Mital S, Magneson A, Loke KE, Liao J, Forfia PR, Hintze TH. Simvastatin acts synergistically with ACE inhibitors or amlodipine to decrease oxygen consumption in rat hearts. J Cardiovasc Pharmacol 2000;36(2):248-254.